4.5 Article

Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry

期刊

MYCOSES
卷 60, 期 4, 页码 273-279

出版社

WILEY
DOI: 10.1111/myc.12595

关键词

Geotrichum; invasive fungal diseases; Saprochaete

资金

  1. Astellas Pharma
  2. Pfizer and Scynexis Inc.
  3. Gilead Sciences Inc.
  4. MSD Sharp Dohme GmbH
  5. Basilea Pharmaceutica
  6. F2G Ltd.

向作者/读者索取更多资源

Saprochaete and Geotrichum spp. are rare emerging fungi causing invasive fungal diseases in immunosuppressed patients and scarce evidence is available for treatment decisions. Among 505 cases of rare IFD from the FungiScope registry, we identified 23 cases of invasive infections caused by these fungi reported from 10 countries over a 12-year period. All cases were adults and previous chemotherapy with associated neutropenia was the most common co-morbidity. Fungaemia was confirmed in 14 (61%) cases and deep organ involvement included lungs, liver, spleen, central nervous system and kidneys. Fungi were S.capitata (n=14), S.clavata (n=5), G.candidum (n=2) and Geotrichum spp. (n=2). Susceptibility was tested in 16 (70%) isolates. All S.capitata and S.clavata isolates with the exception of one S.capitata (MIC 4mg/L) isolate had MICs>32mg/L for caspofungin. For micafungin and anidulafungin, MICs varied between 0.25 and >32mg/L. One case was diagnosed postmortem, 22 patients received targeted treatment, with voriconazole as the most frequent first line drug. Overall mortality was 65% (n=15). Initial echinocandin treatment was associated with worse outcome at day 30 when compared to treatment with other antifungals (amphotericin B +/- flucytosine, voriconazole, fluconazole and itraconazole) (P=.036). Echinocandins are not an option for these infections.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据